HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Efficacy of ipriflavone in established osteoporosis and long-term safety.

Abstract
Ipriflavone (i.p.), an isoflavone derivative, is currently used in several countries for prevention and treatment of osteoporosis. Recently, 149 elderly, osteoporotic women (65-79 years) with prevalent vertebral fractures were enrolled in two Italian, multicenter, double-blind, 2-year studies. Women were randomly allocated to receive either oral i.p. (200 mg T.I.D. at meals) or matching placebo, plus 1 g oral calcium daily. One hundred eleven subjects completed the 2-year treatment period. A significant increase in forearm bone mineral density (BMD), measured by dual photon absorptiometry (DPA), was obtained after i.p. treatment. Women receiving the placebo showed only a limited bone loss during the treatment period, probably due to calcium supplement; however, a significant between-treatment difference was obtained in both studies. Urinary hydroxyproline was significantly decreased in i.p.-treated patients, suggesting a reduction in bone turnover rate. A reduction of incident vertebral fractures was observed in i.p.-treated women compared with control subjects. A significant improvement of bone pain and mobility has also been pointed out in one of the studies. To date, 2769 patients have been treated with i.p., for a total of 3132 patient/years, in 60 clinical studies performed in Italy, Japan, and Hungary and reviewed for long-term safety assessment. The incidence of adverse reactions in ipriflavone-treated patients (14.5%) was similar to that observed in subjects receiving the placebo (16.1%). Side effects were mainly gastrointestinal. Few patients presented reversible modifications of laboratory parameters. The data from the above studies show that long-term treatment with i.p. may be considered safe, and may increase bone density and possibly prevent fractures in elderly patients with established osteoporosis.
AuthorsD Agnusdei, L Bufalino
JournalCalcified tissue international (Calcif Tissue Int) Vol. 61 Suppl 1 Pg. S23-7 ( 1997) ISSN: 0171-967X [Print] United States
PMID9263613 (Publication Type: Clinical Trial, Journal Article, Multicenter Study, Randomized Controlled Trial)
Chemical References
  • Calcium, Dietary
  • Isoflavones
  • ipriflavone
  • Calcitriol
  • Hydroxyproline
Topics
  • Absorptiometry, Photon
  • Administration, Oral
  • Aged
  • Analysis of Variance
  • Bone Density (drug effects)
  • Bone Remodeling (drug effects)
  • Calcitriol (blood)
  • Calcium, Dietary (administration & dosage, therapeutic use)
  • Double-Blind Method
  • Female
  • Humans
  • Hydroxyproline (urine)
  • Incidence
  • Isoflavones (administration & dosage, adverse effects, pharmacology, therapeutic use)
  • Italy (epidemiology)
  • Osteoporosis, Postmenopausal (complications, drug therapy)
  • Prevalence
  • Spinal Fractures (epidemiology, physiopathology, prevention & control)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: